Monitoring efficacy of checkpoint inhibitor therapy in patients with non-small-cell lung cancer
Open Access
- 31 May 2019
- journal article
- research article
- Published by Informa UK Limited in Immunotherapy
- Vol. 11 (9), 769-782
- https://doi.org/10.2217/imt-2019-0039
Abstract
Aim: Radiological criteria alone do not reflect the entire population benefitting from checkpoint inhibitor therapy (CIT). This study aimed to detect patterns to assess CIT efficacy in non-small-cell lung cancer (NSCLC) patients. Materials & methods: We evaluated clinical, radiological and laboratory parameters in a retrospective cohort of NSCLC patients treated with nivolumab. Results: A total of 51 patients were included in the analysis. Most single parameters failed to reflect treatment benefit. Three laboratory parameters (lactate dehydrogenase, C-reactive protein and the neutrophil/lymphocyte ratio) combined in a weighted score could predict benefit with a sensitivity of 92.3% and a hazard ratio of 0.31 (95% CI: 0.16-0.59) in an early phase of therapy. Sorting patients by score showed a 1-year survival of 36% in those predicted as not benefitting versus 68% in those predicted to benefit. Conclusion: A weighted score integrating common serum markers could help detect patients benefitting from checkpoint inhibitors during ongoing CIT.Keywords
This publication has 36 references indexed in Scilit:
- Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art?Journal of Thoracic Oncology, 2015
- Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trialThe Lancet Oncology, 2015
- Nivolumab in NSCLC: latest evidence and clinical potentialTherapeutic Advances in Medical Oncology, 2015
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012International Journal of Cancer, 2014
- The Diagnosis and Treatment of Pseudoprogression, Radiation Necrosis and Brain Tumor RecurrenceInternational Journal of Molecular Sciences, 2014
- CRP evaluation in non-small cell lung cancerEgyptian Journal of Chest Diseases and Tuberculosis, 2014
- Evaluation of pseudoprogression in patients with glioblastoma multiforme using dynamic magnetic resonance imaging with ferumoxytol calls RANO criteria into questionNeuro-Oncology, 2014
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerThe New England Journal of Medicine, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerThe New England Journal of Medicine, 2012
- High-Sensitivity C-Reactive Protein and CancerJournal of Epidemiology, 2011